{"id":5670,"date":"2024-03-26T06:39:12","date_gmt":"2024-03-26T11:39:12","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5670"},"modified":"2025-06-27T11:20:37","modified_gmt":"2025-06-27T16:20:37","slug":"nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308bMCO-010\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u5bfe\u7167\u8a66\u9a13\u3067\u826f\u597d\u306a\u30c8\u30c3\u30d7\u30e9\u30a4\u30f3\u7d50\u679c\u3092\u767a\u8868"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<ul type=\"disc\">\n<li><strong><i>MCO-010 \u306f\u7d71\u8a08\u7684\u6709\u610f\u6027\u3092\u3082\u3063\u3066\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u304a\u3088\u3073\u4e3b\u8981\u306a\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3092\u9054\u6210\u3057\u3001\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u306f\u767a\u751f\u3057\u307e\u305b\u3093\u3067\u3057\u305f<\/i><\/strong><\/li>\n<li><strong><i>\u30d5\u30a7\u30fc\u30ba\u304b\u3089\u306e\u30c7\u30fc\u30bf\u00a0<span class=\"xn-money\">2b<\/span>\u00a0RESTORE\u8a66\u9a13\u306f\u3001\u7db2\u819c\u306e\u9032\u884c\u6027\u304a\u3088\u3073\u6c38\u7d9a\u7684\u306a\u795e\u7d4c\u5909\u6027\u3092\u6709\u3059\u308b\u6cd5\u7684\u76f2\u4eba\u306b\u304a\u3051\u308b\u81e8\u5e8a\u7684\u306b\u610f\u5473\u306e\u3042\u308b\u8996\u529b\u6539\u5584\u3092\u5b9f\u8a3c\u3059\u308b<\/i><\/strong><\/li>\n<li><strong><i>RESTORE \u306f\u3001\u907a\u4f1d\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308b\u5909\u7570\u306b\u4f9d\u5b58\u3057\u306a\u3044\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u521d\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u5bfe\u7167\u8a66\u9a13\u3067\u3059<\/i><\/strong><\/li>\n<li><strong><i>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306f\u30012024 \u5e74\u5f8c\u534a\u306b\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40 (FDA) \u306b\u751f\u7269\u88fd\u5264\u30e9\u30a4\u30bb\u30f3\u30b9\u7533\u8acb\u66f8 (BLA) \u3092\u63d0\u51fa\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/i><\/strong><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span>,\u00a0<span class=\"xn-chron\">2024 \u5e74 3 \u6708 26 \u65e5<\/span> \u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u304a\u3088\u3073\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3059\u308b\u5f8c\u671f\u81e8\u5e8a\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b\u540c\u793e\u306f\u672c\u65e5\u30012\u5e74\u9593\u306e\u30d5\u30a7\u30fc\u30ba\u7d42\u4e86\u5f8c\u306b\u826f\u597d\u306a\u30c8\u30c3\u30d7\u30e9\u30a4\u30f3\u306e\u7d50\u679c\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u30ea\u30fc\u30c9\u30d7\u30ed\u30b0\u30e9\u30e0 MCO-010 \u306e\u30e9\u30f3\u30c0\u30e0\u5316\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u3092\u5fa9\u5143\u3059\u308b<i>,<\/i>\u00a0\u9032\u884c\u6027\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u3088\u308b\u6c38\u4e45\u7684\u304b\u3064\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u306e\u305f\u3081\u306e\u3001\u5909\u7570\u306b\u4f9d\u5b58\u3057\u306a\u3044\u907a\u4f1d\u5b50\u6cbb\u7642\u3002<\/p>\n<p>\u3053\u306e\u8a66\u9a13\u306f\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3092\u9054\u6210\u3057\u3001\u9ad8\u7528\u91cf\uff080.337 LogMAR; p=0.021\uff09\u3068\u4f4e\u7528\u91cf\uff080.382 LogMAR; p=0.029\uff09\u306e\u4e21\u65b9\u306752\u9031\u76ee\u306b\u6700\u9ad8\u77ef\u6b63\u8996\u529b\uff08BCVA\uff09\u304c\u7d71\u8a08\u7684\u306b\u6709\u610f\u306b\u6539\u5584\u3057\u305f\u3053\u3068\u3092\u793a\u3057\u307e\u3057\u305f\u3002\u6cbb\u7642\u30b0\u30eb\u30fc\u30d7\u3068\u507d\u5bfe\u7167\u30b0\u30eb\u30fc\u30d7\u306e\u6bd4\u8f03 (0.050 LogMAR)\u3002\u30d5\u30a7\u30fc\u30ba\u00a0<span class=\"xn-money\">2b<\/span>\u00a0RESTORE\u8a66\u9a13\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u304a\u3044\u3066\u3001\u81e8\u5e8a\u7684\u306b\u91cd\u8981\u306aBCVA &gt; 0.3 LogMAR\u306e\u95be\u5024\u3092\u8d85\u3048\u308b\u6539\u5584\u3092\u7d71\u8a08\u7684\u306b\u6709\u610f\u306a\u5f62\u3067\u5b9f\u8a3c\u3057\u305f\u552f\u4e00\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\u3067\u3042\u308b\u3002.<\/p>\n<p>\u8996\u899a\u6a5f\u80fd\u306e\u6539\u5584\u306f\u7814\u7a76\u306e52\u9031\u76ee\u4ee5\u964d\u3082\u6301\u7d9a\u307e\u305f\u306f\u5897\u52a0\u3057\u3066\u304a\u308a\u3001MCO-010\u306e1\u56de\u306e\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u306e\u6301\u7d9a\u7684\u306a\u52b9\u679c\u304c\u5b9f\u8a3c\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u4e3b\u8981\u306a\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3067\u3042\u308b 76 \u9031\u76ee\u306e BCVA \u6539\u5584\u306f\u3001\u5bfe\u7167\u7fa4\u3068\u6bd4\u8f03\u3057\u3066\u9ad8\u7528\u91cf\u6cbb\u7642\u7fa4\u3067\u7d71\u8a08\u7684\u306b\u6709\u610f\u3067\u3057\u305f (0.539 LogMAR; p=0.001)\u3002 76\u9031\u76ee\u3067\u306f\u3001\u4f4e\u7528\u91cf\u6cbb\u7642\u7fa4\u306eBCVA\u306e\u6539\u5584\u306f\u5bfe\u7167\u3068\u6bd4\u8f03\u3057\u3066\u7d71\u8a08\u7684\u306b\u6709\u610f\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f(0.374 LogMAR; p=0.065)<i>.<\/i>\u00a0\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u521d\u671f\u306e\u7b2c 1\/2a \u76f8\u975e\u76f2\u691c\u8a66\u9a13\u3067\u4ee5\u524d\u306b\u89b3\u5bdf\u3055\u308c\u305f\u7d50\u679c\u3068\u4e00\u81f4\u3057\u3066\u3044\u307e\u3059\u3002\u9ad8\u7528\u91cf\u306e MCO-010 (1.2E11gc\/\u773c) \u304c\u5546\u696d\u7528\u91cf\u3068\u306a\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n<p>\u4e8b\u524d\u306b\u6307\u5b9a\u3055\u308c\u305f\u5225\u306e\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u3067\u306f\u3001\u65b0\u3057\u3044\u591a\u8f1d\u5ea6\u5f62\u72b6\u5f01\u5225\u3068y\u79fb\u52d5\u5ea6\u30c6\u30b9\u30c8\u306e\u8907\u5408\u6a5f\u80fd\u8a55\u4fa1\u9805\u76ee\u306f\u300152\u9031\u76ee\u306b\u9ad8\u7528\u91cf\u6cbb\u7642\u7fa4\u3068\u4f4e\u7528\u91cf\u6cbb\u7642\u7fa4\u306e\u4e21\u65b9\u306789%\u53cd\u5fdc\u7387\u3092\u793a\u3057\u3001\u8996\u529b\u306e\u3055\u3089\u306a\u308b\u30b5\u30dd\u30fc\u30c8\u3092\u63d0\u4f9b\u3057\u307e\u3057\u305f\u3002 MCO-010\u6295\u4e0e\u5f8c\u306b\u6539\u5584\u3002\u3053\u306e\u81e8\u5e8a\u8a66\u9a13\u304b\u3089\u306e\u8ffd\u52a0\u30c7\u30fc\u30bf\u306f\u3001\u8996\u899a\u3068\u773c\u79d1\u5b66\u7814\u7a76\u5354\u4f1a\u306e\u5e74\u6b21\u5b66\u8853\u4f1a\u8b70\u3067\u306e\u767a\u8868\u3092\u76ae\u5207\u308a\u306b\u3001\u4eca\u5f8c\u6570\u304b\u6708\u4ee5\u5185\u306e\u4e00\u9023\u306e\u5b66\u8853\u4f1a\u8b70\u3067\u767a\u8868\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002\u00a0<span class=\"xn-chron\">2024 \u5e74 5 \u6708 6 \u65e5<\/span>\u3001 \u3067\u00a0<span class=\"xn-location\">\u30ef\u30b7\u30f3\u30c8\u30f3\u5dde\u30b7\u30a2\u30c8\u30eb<\/span>\u3001 \u306b\u3088\u308b\u00a0<span class=\"xn-person\">\u30a2\u30ec\u30f3\u30fb\u30db\u30fc<\/span>\u3001\u533b\u5b66\u535a\u58eb\u3001\u30a6\u30a3\u30eb\u30ba\u773c\u79d1\u75c5\u9662\u306e\u7db2\u819c\u7814\u7a76\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u304a\u3088\u3073\u7db2\u819c\u30b5\u30fc\u30d3\u30b9\u306e\u5171\u540c\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u3002<\/p>\n<p>MCO-010 \u306f\u4e00\u822c\u306b\u5fcd\u5bb9\u6027\u304c\u826f\u597d\u3067\u3001\u4ee5\u524d\u306e\u7814\u7a76\u3068\u4e00\u81f4\u3057\u3066\u3001\u6cbb\u7642\u306b\u95a2\u9023\u3057\u305f\u91cd\u7be4\u306a\u6709\u5bb3\u4e8b\u8c61\u306f\u5831\u544a\u3055\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u6700\u3082\u4e00\u822c\u7684\u306a\u6709\u5bb3\u4e8b\u8c61\u306f\u3001\u8efd\u5ea6\u307e\u305f\u306f\u4e2d\u7b49\u5ea6\u306e\u524d\u623f\u7d30\u80de\u304a\u3088\u3073\u9ad8\u773c\u5727\u75c7\u3067\u3057\u305f\u3002\u6cbb\u7642\u7fa4\u3067\u306f\u3001\u773c\u5185\u708e\u3001\u7db2\u819c\u708e\u3001\u7db2\u819c\u8840\u7ba1\u708e\u3001\u7db2\u819c\u9589\u585e\u6027\u8840\u7ba1\u708e\u3001\u773c\u5727\u4f4e\u4e0b\u306a\u3069\u306e\u773c\u5185\u708e\u75c7\u306b\u95a2\u9023\u3059\u308b\u7279\u306b\u8208\u5473\u6df1\u3044\u6709\u5bb3\u4e8b\u8c61\u306f\u5831\u544a\u3055\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002<\/p>\n<p>\u201c\u300c\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u3001\u5b8c\u5168\u306b\u5931\u660e\u3057\u305f\u60a3\u8005\u3092\u542b\u3080\u591a\u304f\u306e\u60a3\u8005\u3067\u3001\u8457\u3057\u3044\u8996\u529b\u56de\u5fa9\u304c\u898b\u3089\u308c\u307e\u3057\u305f\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30c7\u30f4\u30a3\u30c3\u30c9\u30fb\u30dc\u30a4\u30e4\u30fc<\/span>\u3001MD\u306f\u6cbb\u9a13\u306e\u7814\u7a76\u8005\u3067\u3042\u308a\u3001\u773c\u79d1\u306e\u975e\u5e38\u52e4\u81e8\u5e8a\u6559\u6388\u3067\u3059\u3002\u00a0<span class=\"xn-org\">\u5357\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5927\u5b66<\/span>\u00a0\u30b1\u30c3\u30af\u533b\u79d1\u5927\u5b66\u3002\u300cMCO-010\u306b\u3088\u308b\u6cbb\u7642\u3092\u53d7\u3051\u305f\u591a\u304f\u306e\u60a3\u8005\u306f\u3001\u4e3b\u8981\u306a\u8996\u6a5f\u80fd\u691c\u67fb\u3067\u6e2c\u5b9a\u53ef\u80fd\u306a\u81e8\u5e8a\u7684\u306b\u610f\u7fa9\u306e\u3042\u308b\u52b9\u679c\u3092\u5f97\u3066\u304a\u308a\u3001\u3053\u306e\u52b9\u679c\u306f\u6a5f\u80fd\u7684\u8996\u529b\u8a55\u4fa1\u306b\u304a\u3051\u308b\u540c\u69d8\u306e\u6539\u5584\u306b\u3088\u3063\u3066\u78ba\u8a8d\u3055\u308c\u307e\u3057\u305f\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u3053\u306e\u8870\u5f31\u6027\u75be\u60a3\u306b\u82e6\u3057\u3080\u60a3\u8005\u306e\u751f\u6d3b\u306b\u3001\u80af\u5b9a\u7684\u304b\u3064\u610f\u7fa9\u306e\u3042\u308b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u307e\u3059\u3002\u300d\u201c<\/p>\n<p>\u3053\u308c\u3089\u306e\u7d50\u679c\u306b\u57fa\u3065\u3044\u3066\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306f\u4e16\u754c\u7684\u306a\u898f\u5236\u304a\u3088\u3073\u5546\u696d\u5316\u6226\u7565\u3092\u5b9f\u884c\u3059\u308b\u6700\u521d\u306e\u30b9\u30c6\u30c3\u30d7\u3068\u3057\u3066\u30012024 \u5e74\u5f8c\u534a\u306b\u7c73\u56fd FDA \u306b BLA \u3092\u63d0\u51fa\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n<p>\u201c\u300cMCO-010\u304c\u9032\u884c\u6027\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u6539\u5584\u306b\u52b9\u679c\u304c\u3042\u308b\u53ef\u80fd\u6027\u3092\u79d8\u3081\u3066\u3044\u308b\u3053\u3068\u3092\u77e5\u308a\u3001\u5927\u5909\u5b09\u3057\u304f\u601d\u3044\u307e\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30a2\u30eb\u30b7\u30e3\u30c9\u30fbM\u30fb\u30cf\u30ca\u30cb<\/span>\u3001MD\u3001MA\u3001FASRS\u3001Sierra Eye Associates \u306e\u81e8\u5e8a\u7814\u7a76\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u304a\u3088\u3073\u81e8\u5e8a\u6559\u6388\u00a0<span class=\"xn-org\">\u30cd\u30d0\u30c0\u5927\u5b66\u30ea\u30ce\u6821<\/span>\u00a0\u533b\u5b66\u90e8\u3002\u300c\u3053\u308c\u306f\u773c\u79d1\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u5206\u91ce\u306b\u3068\u3063\u3066\u6975\u3081\u3066\u91cd\u8981\u306a\u77ac\u9593\u3067\u3059\u3002\u73fe\u5728\u6709\u52b9\u306a\u6cbb\u7642\u6cd5\u304c\u306a\u304f\u3001\u6c38\u4e45\u7684\u306a\u8996\u529b\u55aa\u5931\u306b\u3064\u306a\u304c\u308b\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3057\u3001\u5909\u7570\u306e\u7a2e\u985e\u3092\u554f\u308f\u306a\u3044\u785d\u5b50\u4f53\u5185\u6295\u4e0e\u306b\u3088\u308b\u6cbb\u7642\u6cd5\u304c\u958b\u767a\u3055\u308c\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u304b\u3089\u3067\u3059\u3002\u300d\u201c<\/p>\n<p>\u201c\u300c\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306f\u3001\u5149\u907a\u4f1d\u5b66\u3092\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306e\u305f\u3081\u306e\u5177\u4f53\u7684\u306a\u6cbb\u7642\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3078\u3068\u767a\u5c55\u3055\u305b\u308b\u6700\u524d\u7dda\u306b\u7acb\u3063\u3066\u3044\u307e\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u5171\u540c\u5275\u696d\u8005\u517c\u6700\u9ad8\u7d4c\u55b6\u8cac\u4efb\u8005\u3067\u3042\u308b\u5f7c\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300cRESTORE\u8a66\u9a13\u306e76\u9031\u76ee\u306e\u6700\u65b0\u89e3\u6790\u304b\u3089\u5f97\u3089\u308c\u305f\u8aac\u5f97\u529b\u306e\u3042\u308b\u30c7\u30fc\u30bf\u306f\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u591a\u7528\u9014\u306aMCO\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u6709\u52b9\u6027\u3092\u3055\u3089\u306b\u88cf\u4ed8\u3051\u308b\u3082\u306e\u3067\u3042\u308a\u3001\u3053\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u3068\u52a0\u9f62\u9ec4\u6591\u5909\u6027\u75c7\uff08AMD\uff09\u306b\u3088\u308b\u5730\u56f3\u72b6\u840e\u7e2e\uff08GA\uff09\u306e\u4e21\u65b9\u306b\u304a\u3051\u308b\u5f53\u793e\u306e\u62e1\u5927\u3059\u308b\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u63a8\u9032\u3057\u3066\u3044\u307e\u3059\u3002\u8a66\u9a13\u53c2\u52a0\u8005\u3068\u305d\u306e\u3054\u5bb6\u65cf\u3001\u6cbb\u9a13\u8cac\u4efb\u533b\u5e2b\u3001\u305d\u3057\u3066\u3053\u306e\u753b\u671f\u7684\u306a\u8a66\u9a13\u3068\u305d\u306e\u6210\u529f\u306b\u8ca2\u732e\u3057\u3066\u304f\u3060\u3055\u3063\u305f\u3059\u3079\u3066\u306e\u65b9\u3005\u306b\u5fc3\u304b\u3089\u611f\u8b1d\u7533\u3057\u4e0a\u3052\u307e\u3059\u3002\u300d\u201c<\/p>\n<p>\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u907a\u4f1d\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308b\u7a81\u7136\u5909\u7570\u975e\u4f9d\u5b58\u578b\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u6709\u52b9\u6027\u3092\u793a\u3059\u6700\u521d\u306e\u8a3c\u62e0\u3068\u306a\u308b\u3002\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u30d9\u30af\u30bf\u30fc\u8a2d\u8a08\u3001\u88fd\u9020\u3001\u81e8\u5e8a\u8a66\u9a13\u8a2d\u8a08\u3001\u3055\u3089\u306b\u306f\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u306b\u5bfe\u3059\u308b\u65b0\u305f\u306a\u6a5f\u80fd\u7684\u8996\u899a\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u306e\u958b\u767a\u306a\u3069\u3001MCO-010 \u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u3042\u3089\u3086\u308b\u5074\u9762\u306b\u308f\u305f\u308b 10 \u5e74\u4ee5\u4e0a\u306b\u308f\u305f\u308b\u9769\u65b0\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u201c\u300c\u3053\u308c\u3089\u306e\u6210\u679c\u306f\u3001\u6570\u591a\u304f\u306e\u732e\u8eab\u7684\u306a\u500b\u4eba\u306b\u3088\u308b10\u5e74\u4ee5\u4e0a\u306b\u308f\u305f\u308b\u7814\u7a76\u306e\u96c6\u5927\u6210\u3067\u3042\u308a\u3001\u5f53\u793e\u72ec\u81ea\u306e\u5e83\u5e2f\u57df\u3001\u9ad8\u611f\u5ea6\u3001\u9ad8\u901f\u306aMCO-010\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u53ef\u80fd\u6027\u3092\u5f37\u8abf\u3059\u308b\u3082\u306e\u3067\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u5171\u540c\u5275\u8a2d\u8005\u3001\u793e\u9577\u517c\u6700\u9ad8\u79d1\u5b66\u8cac\u4efb\u8005\u3067\u3042\u308b\u535a\u58eb\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u4eca\u56de\u306e\u6210\u679c\u306f\u3001\u907a\u4f1d\u5b50\u5909\u7570\u306e\u7a2e\u985e\u3092\u554f\u308f\u306a\u3044\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u5206\u91ce\u306b\u304a\u3051\u308b\u91cd\u8981\u306a\u7bc0\u76ee\u3067\u3042\u308a\u3001\u5149\u907a\u4f1d\u5b66\u304c\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u6709\u671b\u3067\u3042\u308b\u3053\u3068\u3092\u78ba\u56fa\u305f\u308b\u3082\u306e\u306b\u3057\u307e\u3057\u305f\u3002\u56fd\u7acb\u773c\u7814\u7a76\u6240\uff08NIH\uff09\u304a\u3088\u3073\u5171\u540c\u7814\u7a76\u8005\u306e\u7686\u69d8\u306b\u306f\u3001MCO\u7642\u6cd5\u306e\u6cbb\u7642\u53ef\u80fd\u6027\u306e\u5b9f\u73fe\u306b\u591a\u5927\u306a\u8ca2\u732e\u3092\u3057\u3066\u3044\u305f\u3060\u304d\u3001\u5fc3\u3088\u308a\u611f\u8b1d\u7533\u3057\u4e0a\u3052\u307e\u3059\u3002\u3053\u306e\u6210\u679c\u306f\u3001\u6839\u672c\u7684\u306a\u907a\u4f1d\u5b50\u5909\u7570\u306e\u7a2e\u985e\u306b\u95a2\u308f\u3089\u305a\u3001\u60a3\u8005\u3055\u3093\u306e\u8996\u529b\u56de\u5fa9\u3078\u306e\u5e0c\u671b\u3092\u3082\u305f\u3089\u3059\u3082\u306e\u3067\u3059\u3002\u300d\u201c<\/p>\n<p><b>RESTORE \u30c8\u30e9\u30a4\u30a2\u30eb\u306e\u8a73\u7d30<br class=\"dnr\" \/><\/b>\u30de\u30eb\u30c1\u30bb\u30f3\u30bf\u30fc\u3001\u30d5\u30a7\u30fc\u30ba\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u3053\u306e\u8a66\u9a13\u3067\u306f\u3001\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u60a3\u304628\u4eba\u306e\u88ab\u9a13\u8005\u304c\u7121\u4f5c\u70ba\u306b\u5272\u308a\u4ed8\u3051\u3089\u308c\u3001RP\u306e\u81e8\u5e8a\u8a3a\u65ad\u304c\u78ba\u8a8d\u3055\u308c\u307e\u3057\u305f\u3002\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u6e2c\u5b9a\u304a\u3088\u3073\u7814\u7a76\u4ecb\u5165\u306e\u524d\u306b\u540c\u610f\u3092\u64a4\u56de\u3057\u305f\u7121\u4f5c\u70ba\u5316\u88ab\u9a13\u8005 1 \u540d\u306f\u3001mITT \u96c6\u56e3\u306b\u306f\u542b\u307e\u308c\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u5831\u544a\u3055\u308c\u305f\u7d50\u679c\u306f\u3001\u7814\u7a76\u773c\uff08MCO-010\u307e\u305f\u306f\u5bfe\u7167\uff09\u3078\u306e\u4ecb\u5165\u3092\u53d7\u3051\u305f\u3059\u3079\u3066\u306e\u7121\u4f5c\u70ba\u5316\u5bfe\u8c61\u8005\uff08MCO-010\u30b0\u30eb\u30fc\u30d7\u306e18\u4eba\u306e\u5bfe\u8c61\u8005\u304a\u3088\u3073\u5bfe\u7167\u7fa4\u306e9\u4eba\u306e\u5bfe\u8c61\u8005\uff09\u3092\u542b\u3080mITT\u96c6\u56e3\u304b\u3089\u306e\u3082\u306e\u3067\u3042\u308b\u3002\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u4e3b\u8981\u306a\u526f\u6b21\u8a55\u4fa1\u9805\u76ee\u306b\u3064\u3044\u3066\u306f\u3001\u30d5\u30e9\u30a4\u30d6\u30eb\u30af\u8996\u529b\u691c\u67fb\u3067\u6e2c\u5b9a\u3057\u305fBCVA\u3092\u8a55\u4fa1\u3059\u308b\u305f\u3081\u306b\u3001\u88ab\u9a13\u8005\u30922\u5e74\u9593\u306b\u308f\u305f\u3063\u3066\u8907\u6570\u306e\u6642\u70b9\u3067\u8a55\u4fa1\u3057\u307e\u3057\u305f\u3002<\/p>\n<ul type=\"disc\">\n<li>\u53cd\u5fa9\u6e2c\u5b9a\u306e\u7dda\u5f62\u6df7\u5408\u52b9\u679c\u30e2\u30c7\u30eb (MMRM) \u304c\u4e3b\u8981\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3068\u4e3b\u8981\u306a\u526f\u6b21\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3067\u5b9f\u884c\u3055\u308c\u3001\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u5f8c\u306e\u3059\u3079\u3066\u306e\u6765\u9662\u304b\u3089\u306e\u8996\u529b\u30c7\u30fc\u30bf\u304c\u30e2\u30c7\u30eb\u306b\u542b\u307e\u308c\u3001\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u8996\u529b\u304c\u5171\u5909\u91cf\u3068\u3057\u3066\u4f7f\u7528\u3055\u308c\u307e\u3057\u305f\u3002<\/li>\n<li>\u6cbb\u7642\u7fa4\u9593\u306e\u6bd4\u8f03\u306f\u3001\u5bfe\u7167\u3068\u306e\u591a\u91cd\u6bd4\u8f03\u3092\u8abf\u6574\u3059\u308b\u305f\u3081\u306b\u30db\u30c3\u30db\u30d9\u30eb\u30b0\u6cd5\u3092\u4f7f\u7528\u3057\u3066\u5b9f\u65bd\u3055\u308c\u307e\u3057\u305f\u3002 MMRM \u30e2\u30c7\u30eb\u304b\u3089\u5f97\u3089\u308c\u305f\u7d50\u679c\u3092\u4f7f\u7528\u3059\u308b\u3068\u3001\u00a0<i>p-<\/i>MCO-010 \u30b0\u30eb\u30fc\u30d7\u3068\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u306e 2 \u3064\u306e\u6bd4\u8f03\u304b\u3089\u5f97\u3089\u308c\u305f\u5024\u306f\u3001\u6700\u5927\u304b\u3089\u6700\u5c0f\u306e\u9806\u306b\u4e26\u3079\u3089\u308c\u307e\u3057\u305f\u3002<\/li>\n<li>\u5831\u544a\u3055\u308c\u3066\u3044\u308b\u4e00\u6b21\u304a\u3088\u3073\u4e3b\u8981\u306a\u4e8c\u6b21\u8996\u529b\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u306e\u7d50\u679c\u306f\u3001\u898f\u5236\u4e0a\u306e\u8b70\u8ad6\u306b\u57fa\u3065\u3044\u3066\u3044\u307e\u3059\u3002\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4123320-1&h=1781377654&u=https%3A%2F%2Fnanostherapeutics.com%2F2024%2F01%2F18%2Fnanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa%2F&a=as+previously+announced+on+January+18%2C+2024\" target=\"_blank\" rel=\"nofollow noopener\">\u4ee5\u524d\u306b\u767a\u8868\u3055\u308c\u305f\u3088\u3046\u306b\u00a0<span class=\"xn-chron\">2024 \u5e74 1 \u6708 18 \u65e5<\/span><\/a>\u3001\u305d\u3057\u3066\u3001\u7814\u7a76\u306e\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3092\u5f53\u521d\u610f\u56f3\u3055\u308c\u305f\u7814\u7a76\u306e\u76ee\u7684\u306b\u5408\u308f\u305b\u307e\u3059\u3002\u6539\u8a02\u3055\u308c\u305f\u7d71\u8a08\u89e3\u6790\u8a08\u753b (SAP) \u304c\u6700\u7d42\u6c7a\u5b9a\u3055\u308c\u3001\u7814\u7a76\u306e 76 \u9031\u4ee5\u964d\u306e\u6642\u70b9\u304c\u5b8c\u4e86\u3059\u308b\u524d\u306b\u898f\u5236\u5f53\u5c40\u306b\u63d0\u51fa\u3055\u308c\u307e\u3057\u305f\u3002<\/li>\n<li>\u6a5f\u80fd\u7684\u8996\u899a\u306f\u3001\u65e5\u5e38\u751f\u6d3b\u6d3b\u52d5\u3067\u906d\u9047\u3059\u308b\u3055\u307e\u3056\u307e\u306a\u5149\u30ec\u30d9\u30eb\u306e\u4e0b\u3067\u306e\u7269\u4f53\u8a8d\u8b58\u307e\u305f\u306f\u79fb\u52d5\u30b3\u30fc\u30b9\u306e\u30ca\u30d3\u30b2\u30fc\u30b7\u30e7\u30f3\u306b\u304a\u3051\u308b\u88ab\u9a13\u8005\u306e\u30d1\u30d5\u30a9\u30fc\u30de\u30f3\u30b9\u3092\u8a55\u4fa1\u3059\u308b\u3053\u3068\u306b\u3088\u3063\u3066\u8a55\u4fa1\u3055\u308c\u307e\u3057\u305f\u3002<\/li>\n<\/ul>\n<p>\u4e3b\u306a\u6709\u52b9\u6027\u7d50\u679c\u306e\u6982\u8981\u306f\u6b21\u306e\u3068\u304a\u308a\u3067\u3059\u3002<\/p>\n<div>\n<div class=\"divOverflow\">\n<div class=\"table-responsive\">\n<table class=\"prnbcc\" border=\"0\" width=\"\" cellspacing=\"0\" cellpadding=\"1\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"2\" width=\"\" height=\"\"><\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>\u4e3b\u8981\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8:<\/i><\/b><i>\u00a052\u9031\u76ee\u306eBCVA<\/i><\/span><\/p>\n<\/td>\n<td class=\"prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnsblb1\" colspan=\"2\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>\u4e3b\u8981\u306a\u526f\u6b21\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8:<\/i><\/b><i>\u00a076\u9031\u76ee\u306eBCVA<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>LogMAR \u306e\u5909\u5316<br class=\"dnr\" \/>\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3 (\u5e73\u5747\u5024 \u00b1 SEM)<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>P\u5024<\/i><\/span><\/p>\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>\u5bfe\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>LogMAR \u306e\u5909\u5316<br class=\"dnr\" \/>\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3 (\u5e73\u5747\u5024 \u00b1 SEM)<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>P\u5024<\/i><\/span><\/p>\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>\u5bfe\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>\u9ad8\u7528\u91cf MCO-010<\/i><\/b><\/span><\/p>\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>(1.2E11 gc\u3001N=9)<\/i><\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>-0.337 \u00b10.0829<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>0.0209<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>-0.539 \u00b1 0.1032<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>0.0014<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>\u4f4e\u7528\u91cf MCO-010<\/i><\/b><\/span><\/p>\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>(0.9E11 gc\u3001N=9)<\/i><\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>-0.382 \u00b10.1244<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>0.0290<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>-0.374 \u00b1 0.1332<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>0.0652<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>\u507d\u306e\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb<\/i><\/b><\/span><\/p>\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b><i>(N=9)<\/i><\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>-0.050 \u00b10.0717<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>\u2014-<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>-0.078 \u00b1 0.0737<\/i><\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><i>\u2014-<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306f\u3001\u7db2\u819c\u306e\u5149\u53d7\u5bb9\u7d30\u80de\u304c\u6642\u9593\u3068\u3068\u3082\u306b\u5909\u6027\u3057\u3001\u8996\u529b\u969c\u5bb3\u3084\u6700\u7d42\u7684\u306b\u306f\u5931\u660e\u306b\u81f3\u308b\u7a00\u306a\u907a\u4f1d\u6027\u75be\u60a3\u7fa4\u306e\u7dcf\u79f0\u3067\u3059\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306f\u3001100\u7a2e\u985e\u4ee5\u4e0a\u306e\u907a\u4f1d\u5b50\u5909\u7570\u306b\u95a2\u9023\u3057\u3066\u3044\u308b\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u7c73\u56fd\u3067\u306f\u7d0410\u4e07\u4eba\u3001\u4e16\u754c\u3067\u306f\u63a8\u5b9a200\u4e07\u4eba\u304cRP\u306b\u7f79\u60a3\u3057\u3066\u304a\u308a\u3001\u907a\u4f1d\u6027\u5931\u660e\u306e\u4e3b\u306a\u539f\u56e0\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002.<\/p>\n<p><b>MCO-010\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u73fe\u5728\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u306f\u3001\u7279\u5b9a\u306e\u907a\u4f1d\u5b50\u5909\u7570\u3092\u6301\u3064\u60a3\u8005\u306e\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u308b\u304c\u3001\u7db2\u819c\u5916\u5c64\u7d30\u80de\u304c\u5909\u6027\u3057\u305f\u9032\u884c\u6027\u75be\u60a3\u3067\u306f\u3055\u3089\u306b\u9650\u754c\u304c\u3042\u308b\u3002\u5468\u56f2\u5149\u3067\u6d3b\u6027\u5316\u53ef\u80fd\u306a MCO \u5149\u907a\u4f1d\u5b66\u7684\u5358\u72ec\u7642\u6cd5\u306f\u3001\u8c4a\u5bcc\u306a\u7db2\u819c\u5185\u30cb\u30e5\u30fc\u30ed\u30f3\u3092\u6a19\u7684\u3068\u3057\u3001\u9032\u884c\u3057\u305f RP \u306b\u3088\u308a\u6c38\u4e45\u306b\u5931\u308f\u308c\u305f\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002 MCO-010 (<i>\u30bd\u30f3\u30d4\u30ec\u30c1\u30b2\u30cd\u30fb\u30a4\u30b9\u30c6\u30d1\u30eb\u30dc\u30d9\u30af<\/i>\u3001\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u7528\u61f8\u6fc1\u6db2\uff09\u306f\u3001\u73fe\u5728\u81e8\u5e8a\u8a66\u9a13\u4e2d\u306e\u552f\u4e00\u306e\u5e83\u5e2f\u57df\u3001\u9ad8\u901f\u3001\u9ad8\u5149\u611f\u53d7\u6027\u30aa\u30d7\u30b7\u30f3\u3067\u3059\u3002 MCO-010 \u767a\u73fe\u30ab\u30bb\u30c3\u30c8\u306f\u3001mGluR6 \u30d7\u30ed\u30e2\u30fc\u30bf\u30fc\u30a8\u30f3\u30cf\u30f3\u30b5\u30fc\u3092\u4ecb\u3057\u305f\u53cc\u6975\u7d30\u80de\u30bf\u30fc\u30b2\u30c6\u30a3\u30f3\u30b0\u306b\u3088\u308a\u3001\u73fe\u5b9f\u4e16\u754c\u306e\u74b0\u5883\u3067\u9ad8\u54c1\u8cea\u306e\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u72ec\u81ea\u306e AAV2 \u30d9\u30af\u30bf\u30fc\u306b\u3088\u308a\u3001\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u306b\u3088\u308b\u53cc\u6975\u7d30\u80de\u3078\u306e MCO-010 \u306e\u5f37\u529b\u306a\u5f62\u8cea\u5c0e\u5165\u304c\u53ef\u80fd\u306b\u306a\u308a\u307e\u3059\u3002\u9032\u884cRP\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u306e\u7b2c1\/2a\u76f8\u8a66\u9a13\u3067\u306f\u3001\u826f\u597d\u306a\u5b89\u5168\u6027\u3068\u7528\u91cf\u4f9d\u5b58\u7684\u306a\u8996\u529b\u306e\u6539\u5584\u304c\u5b9f\u8a3c\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306f\u3001\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306b\u5bfe\u3057\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306b\u306f\u6cbb\u7642\u6cd5\u304c\u5b58\u5728\u3057\u306a\u3044\u3002\u540c\u793e\u306e\u4e3b\u8981\u958b\u767a\u5019\u88dc\u3067\u3042\u308bMCO-010\u306f\u3001\u6700\u8fd1RESTORE\u30d5\u30a7\u30fc\u30ba\u3092\u5b8c\u4e86\u3057\u305f\u3002\u00a0<span class=\"xn-money\">2b<\/span>\u00a0\u7c73\u56fd\u306b\u304a\u3051\u308b\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308b\u591a\u65bd\u8a2d\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u30de\u30b9\u30af\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13(NCT04945772)\u3002\u540c\u793e\u306f\u6700\u8fd1\u3001\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u7642\u6cd5\u306e\u7b2c2\u76f8STARLIGHT\u8a66\u9a13\u3082\u5b8c\u4e86\u3057\u305f\uff08NCT05417126\uff09\u3002 MCO-010 \u306f\u3001RP \u75c5\u3068\u30b7\u30e5\u30bf\u30eb\u30ac\u30eb\u30c8\u75c5\u306e\u4e21\u65b9\u306b\u5bfe\u3057\u3066 FDA \u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068 FDA \u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306e\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001AMD \u306b\u3088\u308b GA \u306b\u5bfe\u3059\u308b\u975e\u30a6\u30a4\u30eb\u30b9\u30ec\u30fc\u30b6\u30fc\u306b\u3088\u308b MCO-020 \u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<p><b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:Nanoscope@argotpartners.com\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscope@argotpartners.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events Data from the Phase\u00a02b\u00a0RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of the retina RESTORE is the first randomized, controlled trial of a mutation-agnostic gene therapy for a genetic disease Nanoscope anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 DALLAS,\u00a0March 26, 2024 \u2014\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced positive top-line results after the completion of the 2-year [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5671,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-26T11:39:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:20:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1374\" \/>\n\t<meta property=\"og:image:height\" content=\"944\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"8\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa\",\"datePublished\":\"2024-03-26T11:39:12+00:00\",\"dateModified\":\"2025-06-27T16:20:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/\"},\"wordCount\":1573,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/NSCOPE_Feature_ResultsPR.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/NSCOPE_Feature_ResultsPR.jpg\",\"datePublished\":\"2024-03-26T11:39:12+00:00\",\"dateModified\":\"2025-06-27T16:20:37+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/NSCOPE_Feature_ResultsPR.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/NSCOPE_Feature_ResultsPR.jpg\",\"width\":1374,\"height\":944},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/03\\\/26\\\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306e\u7121\u4f5c\u70ba\u5316\u6bd4\u8f03\u8a66\u9a13\u3067\u826f\u597d\u306a\u4e3b\u8981\u7d50\u679c\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-03-26T11:39:12+00:00","article_modified_time":"2025-06-27T16:20:37+00:00","og_image":[{"width":1374,"height":944,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"8\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa","datePublished":"2024-03-26T11:39:12+00:00","dateModified":"2025-06-27T16:20:37+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/"},"wordCount":1573,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306e\u7121\u4f5c\u70ba\u5316\u6bd4\u8f03\u8a66\u9a13\u3067\u826f\u597d\u306a\u4e3b\u8981\u7d50\u679c\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg","datePublished":"2024-03-26T11:39:12+00:00","dateModified":"2025-06-27T16:20:37+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/03\/NSCOPE_Feature_ResultsPR.jpg","width":1374,"height":944},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=5670"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5670\/revisions"}],"predecessor-version":[{"id":9051,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5670\/revisions\/9051"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/5671"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=5670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=5670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=5670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}